Joel A Sincavage

Array ( [id] => 9785162 [patent_doc_number] => 20140301982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-09 [patent_title] => 'COMPLEMENT ANTAGONISTS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/206022 [patent_app_country] => US [patent_app_date] => 2014-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 28382 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14206022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10648269 [patent_doc_number] => 09364496 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-14 [patent_title] => 'Custirsen treatment with reduced toxicity' [patent_app_type] => utility [patent_app_number] => 14/207469 [patent_app_country] => US [patent_app_date] => 2014-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 37180 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14207469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13648471 [patent_doc_number] => 09850543 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-26 [patent_title] => Biomarkers associated with BRM inhibition [patent_app_type] => utility [patent_app_number] => 14/777211 [patent_app_country] => US [patent_app_date] => 2014-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 10 [patent_no_of_words] => 20683 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14777211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9785162 [patent_doc_number] => 20140301982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-09 [patent_title] => 'COMPLEMENT ANTAGONISTS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/206022 [patent_app_country] => US [patent_app_date] => 2014-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 28382 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14206022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393961 [patent_doc_number] => 20170014496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'COMBINATION OF VACCINATION AND OX40 AGONISTS' [patent_app_type] => utility [patent_app_number] => 15/124822 [patent_app_country] => US [patent_app_date] => 2014-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 35118 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15124822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10642748 [patent_doc_number] => 09359606 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-07 [patent_title] => 'Anti-clusterin monotherapy for cancer treatment' [patent_app_type] => utility [patent_app_number] => 14/207471 [patent_app_country] => US [patent_app_date] => 2014-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10615 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14207471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11236569 [patent_doc_number] => 09463200 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-10-11 [patent_title] => 'Cell-penetrating oligonucleotides' [patent_app_type] => utility [patent_app_number] => 14/769997 [patent_app_country] => US [patent_app_date] => 2014-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 14480 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14769997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10581144 [patent_doc_number] => 09303263 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-04-05 [patent_title] => 'Aptamers that bind CD271' [patent_app_type] => utility [patent_app_number] => 14/382681 [patent_app_country] => US [patent_app_date] => 2014-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 16 [patent_no_of_words] => 11561 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14382681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10355233 [patent_doc_number] => 20150240239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-27 [patent_title] => 'METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING MATRIX METALLOPROTEINASES 1 BY INTERFERENCE RIBONUCLEIC ACID' [patent_app_type] => utility [patent_app_number] => 14/191628 [patent_app_country] => US [patent_app_date] => 2014-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 4447 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14191628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9562055 [patent_doc_number] => 20140179769 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-26 [patent_title] => 'CANCER-CELL-SPECIFIC CYTOSTATIC AGENT' [patent_app_type] => utility [patent_app_number] => 14/191066 [patent_app_country] => US [patent_app_date] => 2014-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 7018 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14191066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12490689 [patent_doc_number] => 09994843 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-12 [patent_title] => Method for assaying microRNA, cancer therapeutic agent, and medicinal composition containing same for cancer therapy [patent_app_type] => utility [patent_app_number] => 14/767372 [patent_app_country] => US [patent_app_date] => 2014-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 14420 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14767372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9756321 [patent_doc_number] => 20140287023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-25 [patent_title] => '5\'-TRIPHOSPHATE OLIGORIBONUCLEOTIDES' [patent_app_type] => utility [patent_app_number] => 14/177866 [patent_app_country] => US [patent_app_date] => 2014-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 23064 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14177866 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9720876 [patent_doc_number] => 20140256578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-11 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON\'S DISEASE' [patent_app_type] => utility [patent_app_number] => 14/174067 [patent_app_country] => US [patent_app_date] => 2014-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 20749 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14174067 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9616893 [patent_doc_number] => 20140206751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-24 [patent_title] => 'METHODS FOR PRODUCING INTERFERING RNA MOLECULES IN MAMMALIAN CELLS AND THERAPEUTIC USES FOR SUCH MOLECULES' [patent_app_type] => utility [patent_app_number] => 14/164625 [patent_app_country] => US [patent_app_date] => 2014-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 7757 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14164625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9643345 [patent_doc_number] => 20140221457 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-07 [patent_title] => 'AMELIORATING OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASE VIA NOX1 TARGETING' [patent_app_type] => utility [patent_app_number] => 14/164003 [patent_app_country] => US [patent_app_date] => 2014-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 26078 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14164003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10540683 [patent_doc_number] => 09265787 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-23 [patent_title] => 'Combined inhibition of the vitamin D receptor and DNA replication in the treatment of cancer' [patent_app_type] => utility [patent_app_number] => 14/140597 [patent_app_country] => US [patent_app_date] => 2013-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 18 [patent_no_of_words] => 13126 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14140597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9569902 [patent_doc_number] => 20140187615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-03 [patent_title] => 'THERAPEUTIC POLYNUCLEOTIDES, COMPOSITIONS, AND METHODS' [patent_app_type] => utility [patent_app_number] => 14/138690 [patent_app_country] => US [patent_app_date] => 2013-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 11235 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14138690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10176227 [patent_doc_number] => 09206423 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-12-08 [patent_title] => 'Methods of modulating compliance of the trabecular meshwork' [patent_app_type] => utility [patent_app_number] => 14/134991 [patent_app_country] => US [patent_app_date] => 2013-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 36005 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14134991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10601465 [patent_doc_number] => 09322018 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-04-26 [patent_title] => 'Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 14/132999 [patent_app_country] => US [patent_app_date] => 2013-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 72258 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14132999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9875325 [patent_doc_number] => 08962592 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-24 [patent_title] => 'Methods of treating a meiotic kinesin associated disease' [patent_app_type] => utility [patent_app_number] => 14/103520 [patent_app_country] => US [patent_app_date] => 2013-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 11982 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14103520 [rel_patent_id] =>[rel_patent_doc_number] =>)